US equities
|
NVDA
$170.69
▼-4.47%
AMD
$525.31
▲+3.29%
MU
$720.21
▼-1.76%
SPCX
$142.54
▲+0.33%
SNDK
$866.25
▼-2.28%
AVGO
$329.75
▲+3.21%
TSLA
$375.70
▼-0.62%
AAPL
$348.29
▼-0.68%
NVDA
$170.69
▼-4.47%
AMD
$525.31
▲+3.29%
MU
$720.21
▼-1.76%
SPCX
$142.54
▲+0.33%
SNDK
$866.25
▼-2.28%
AVGO
$329.75
▲+3.21%
TSLA
$375.70
▼-0.62%
AAPL
$348.29
▼-0.68%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
iShares Global Healthcare ETF
(NY:
IXJ
)
114.07
-0.89 (-0.77%)
Delayed Quote
Updated: 10:33 AM EST, Nov 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about iShares Global Healthcare ETF
< Previous
1
2
Next >
The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?
↗
November 07, 2026
PJP delivered 32.8% returns over one year with concentrated U.S. pharma exposure, while IXJ offers broader global healthcare diversification and a higher dividend yield.
Via
The Motley Fool
Topics
ETFs
Economy
Which Healthcare ETF Is the Better Buy: iShares’ Global IXJ or First Trust’s Biotech FBT?
↗
October 26, 2026
IXJ offers diversified global exposure at lower cost, while FBT concentrates on biotech with higher volatility and stronger recent returns.
Via
The Motley Fool
Topics
ETFs
IYH Beats IXJ on Returns While Global Fund Offers Higher Yield
↗
October 06, 2026
U.S. healthcare stocks delivered 28.8% gains over one year versus 22.5% for international peers. Both funds carry nearly identical expense ratios and low volatility profiles.
Via
The Motley Fool
Topics
ETFs
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb
↗
January 22, 2026
Via
Stocktwits
Trump Steps Up Pressure On Trading Partners Over Drug Costs, Plans Section 301 Review: Report
↗
October 22, 2025
Via
Stocktwits
Topics
Government
Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure?
↗
September 16, 2026
FHLC delivered 24% returns over one year with a 0.08% expense ratio, while IXJ offers global diversification but trails on performance and costs more to own.
Via
The Motley Fool
Topics
ETFs
State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for Investors
↗
September 13, 2026
XLV's 0.08% expense ratio and 22.7% 1-year return outpace IXJ's global reach, but international diversification comes at a cost.
Via
The Motley Fool
Topics
ETFs
IXJ vs XPH: Global Healthcare ETF or Pharma Focus?
↗
September 11, 2026
XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading.
Via
The Motley Fool
Topics
ETFs
Which Healthcare ETF Is the Better Buy: Vanguard's VHT or iShares' IXJ?
↗
August 25, 2026
VHT charges low fees and holds more than 400 stocks for broader diversification. IXJ's portfolio of 110 holdings includes international exposure -- but comes at a higher cost.
Via
The Motley Fool
Topics
ETFs
iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?
↗
August 08, 2026
XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend.
Via
The Motley Fool
Topics
ETFs
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?
↗
July 23, 2026
VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.
Via
The Motley Fool
Topics
ETFs
Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?
↗
July 23, 2026
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.
Via
The Motley Fool
Topics
ETFs
Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ
↗
July 23, 2026
The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The...
Via
The Motley Fool
Topics
ETFs
Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026?
↗
July 22, 2026
One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.
Via
The Motley Fool
Topics
ETFs
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?
↗
July 22, 2026
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
Via
The Motley Fool
Topics
ETFs
Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?
↗
July 21, 2026
One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies.
Via
The Motley Fool
Topics
ETFs
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?
↗
July 21, 2026
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
Via
The Motley Fool
Topics
ETFs
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
↗
July 20, 2026
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
Via
The Motley Fool
Topics
ETFs
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?
↗
July 20, 2026
IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.
Via
The Motley Fool
Topics
ETFs
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?
↗
July 18, 2026
IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?
Via
The Motley Fool
Topics
ETFs
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?
↗
July 18, 2026
IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.
Via
The Motley Fool
Topics
ETFs
Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF
↗
July 16, 2026
IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield.
Via
The Motley Fool
Topics
ETFs
Fidelity (FHLC) vs. iShares (IXJ): Which Healthcare ETF Delivers Better Value?
↗
June 26, 2026
Compare global reach to domestic focus as these two funds reveal key differences in cost, risk, and portfolio makeup for healthcare investors.
Via
The Motley Fool
Topics
ETFs
U.S. Health Care Depth or Global Industry Reach? VHT vs. IXJ
↗
June 01, 2026
The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S....
Via
The Motley Fool
Topics
ETFs
Intellectual Property
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.
↗
May 27, 2026
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.
Via
The Motley Fool
Topics
ETFs
PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem
↗
May 27, 2026
A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles.
Via
The Motley Fool
Topics
ETFs
INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally?
↗
January 26, 2026
According to a Calcalist report, the company is set to go private after a $1.1 billion acquisition by a fund.
Via
Stocktwits
Topics
Artificial Intelligence
Why Did Corcept Therapeutics Stock Surge Over 14% Today?
↗
January 22, 2026
In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone.
Via
Stocktwits
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?
↗
January 14, 2026
On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.
Via
Stocktwits
Topics
Artificial Intelligence
Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul
↗
December 12, 2025
Via
MarketBeat
< Previous
1
2
Next >
